Who are Placebo to Pentoxifylline oral's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-pentoxifylline-oral.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo to Pentoxifylline oral — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Pentoxifylline oral (Placebo to Pentoxifylline oral) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rheological agent / Phosphodiesterase inhibitor. Area: Cardiovascular / Vascular disease.

phase 3 Rheological agent / Phosphodiesterase inhibitor Non-selective phosphodiesterase inhibitor; multiple targets including adenosine receptors Cardiovascular / Vascular disease Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Pentoxifylline oral (Placebo to Pentoxifylline oral) — UCB Pharma. Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to Pentoxifylline oral TARGET	Placebo to Pentoxifylline oral	UCB Pharma	phase 3	Rheological agent / Phosphodiesterase inhibitor	Non-selective phosphodiesterase inhibitor; multiple targets including adenosine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rheological agent / Phosphodiesterase inhibitor class)

UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Pentoxifylline oral — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-pentoxifylline-oral. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab